Joseph P. Hazelton
President & COOMr. Joseph P. Hazelton, also known as Joe, is President of Dyadic International, Inc. from June 2, 2025 and serves as its Chief Operating Officer since March 26, 2024 and served as its Chief Business Officer since November 09, 2021 until 2024. He is responsible for supporting the global commercialization of the Company’s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. Mr. Hazelton has pharmaceutical industry experience to Dyadic in key growth areas of product and business development, licensing and commercialization. He joins Dyadic from Charleston Laboratories, Inc. He has been the Chief Operating Officer of Charleston Laboratories, Inc. since January 24, 2017 and serves as its Executive Vice President, he is responsible for the strategic management of Charleston’s product and portfolio management, alliance management, regulatory oversight and global commercialization activities. Mr. Hazelton served as the Chief Commercial Officer of Charleston Laboratories, Inc. since May 08, 2014. Mr. Hazelton joined Charleston Laboratories from Novartis Pharmaceuticals Corporation (Novartis), where he was most recently a Member of the U.S. Managed Markets and Multiple Sclerosis (MS) Business Unit leadership teams with primary responsibility for leading the development and execution of the U.S. Managed Markets and Market Access strategic plan for the MS franchise, which includes the blockbuster product Gilenya(R). At Novartis Pharmaceuticals Corporation he ascended to roles of increasing responsibility based on his leadership, innovation and results. While at Novartis, he held leadership positions within the core functions of sales, marketing, market access, pricing, contracting and strategic alliances for various retail and specialty pharmaceuticals across a broad spectrum of therapeutic areas and several blockbuster products. Mr. Hazelton is an effective and talented executive with over 15 years of pharmaceutical experience in roles of increasing responsibility with diverse proficiency in corporate strategy, sales, marketing and managed markets. He is recognized for his knowledge in market access strategy with expertise in market assessment, value proposition development, pricing, reimbursement and contracting strategies. In addition to his work on Gilenya(R), Mr. Hazelton held various responsibilities for multiple blockbuster medications such as Diovan(R) and Lamisil(R) during his tenure with Novartis. Mr. Hazelton received his B.A. from the College of the Holy Cross in Worcester, Mass.
公司職務
- 公司名稱Dyadic International, Inc.股票代碼DYAI職務President & COO共事同僚
